Somewhat Positive Media Coverage Somewhat Unlikely to Affect Alere (ALR) Stock Price
Press coverage about Alere (NYSE:ALR) has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alere earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 46.8762030522492 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Costco Wholesale Corporation’s (COST) Neutral Rating Reaffirmed at Guggenheim (fishinghd.com)
- Head to Head Comparison: Fulgent Genetic (FLGT) vs. Alere (ALR) (americanbankingnews.com)
- ALERE INVESTIGATION INITIATED BY FORMER LOUISIANA … – Markets Insider (markets.businessinsider.com)
- ALERE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick … (prnewswire.com)
- Alere, Inc. breached its 50 day moving average in a Bearish Manner : ALR-US : September 8, 2017 (finance.yahoo.com)
Shares of Alere (ALR) opened at 50.15 on Friday. Alere has a 52-week low of $34.41 and a 52-week high of $50.63. The firm’s market cap is $4.39 billion. The company has a 50-day moving average of $49.63 and a 200 day moving average of $47.06.
Several analysts have recently weighed in on ALR shares. Zacks Investment Research upgraded shares of Alere from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. Canaccord Genuity reissued a “buy” rating and issued a $51.00 price target on shares of Alere in a research report on Monday, May 22nd. BidaskClub downgraded shares of Alere from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. BTIG Research reissued a “hold” rating on shares of Alere in a research report on Wednesday, May 24th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $51.00 price target on shares of Alere in a research report on Thursday, June 1st. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. Alere has an average rating of “Hold” and a consensus price target of $48.00.
ILLEGAL ACTIVITY WARNING: This piece was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/15/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-alere-alr-stock-price.html.
Alere Company Profile
Alere Inc is a provider of health information through diagnostic tests. The Company’s segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus.
Receive News & Ratings for Alere Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alere Inc. and related companies with MarketBeat.com's FREE daily email newsletter.